UFP Tech extends supply pact with Intuitive Surgical to 2029, boosts min volumes

UFP TECHNOLOGIES INC

Amendment No. 27 extends Manufacturing Supply Agreement term by two years, now through Dec 31, 2029.
Materially increases annual minimum volumes for the Company's largest program under the agreement in 2028 and 2029.
Adds a new program to the Supply Agreement, expanding the scope of products supplied to Intuitive Surgical.
Includes volume-based pricing tied to minimum purchase thresholds and cost-sharing provisions; specific terms redacted as confidential.
WSUT's fleet of 22 PSVs (19 Brazilian-built) brings Tidewater's total global OSV fleet to 213 and expands Brazil presence to 28 vessels.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.95

UFP TECHNOLOGIES INC amended Manufacturing Supply Agreement with Intuitive Surgical SARL valued at Extended term to December 31, 2029; materially increased annual minimum volumes for largest program (effective 2026-01-01).

Action: amendment
Agreement: supply
Counterparty: Intuitive Surgical SARL
Value: Extended term to December 31, 2029; materially increased annual minimum volumes for largest program
Effective: 2026-01-01

Exact text from the filing

On February 19, 2026, through a wholly-owned subsidiary, UFP Technologies, Inc. (“UFP” or the “Company”) and Intuitive Surgical SARL, one of the Company’s strategic medical customers (the “Customer”), entered into Amendment No. 27 (the “Amendment”) to the Manufacturing Supply Agreement, dated April 25, 2014 (the “Supply Agreement”, as amended, the “Amended Supply Agreement”).

View on SEC.gov

281 material agreements filed in the last 30 days. Browse all material agreements →

UFP TECHNOLOGIES INC filing history →

Source: SEC EDGAR

accession 0001628280-26-011154

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.